Moreover, our results provide a rationale for the implication of ADC-TAFs in the early ADC cancer cell dissemination observed in clinical settings and for the therapeutic use of MEK inhibitors against the enhanced migratory phenotype of ADC-TAFs (Fig. 6g). Here, MAP2K7 is linked to cancer.